DE60322102D1 - Transdermales buprenorphin-dosierschema zwecks schmerzstillung - Google Patents

Transdermales buprenorphin-dosierschema zwecks schmerzstillung

Info

Publication number
DE60322102D1
DE60322102D1 DE60322102T DE60322102T DE60322102D1 DE 60322102 D1 DE60322102 D1 DE 60322102D1 DE 60322102 T DE60322102 T DE 60322102T DE 60322102 T DE60322102 T DE 60322102T DE 60322102 D1 DE60322102 D1 DE 60322102D1
Authority
DE
Germany
Prior art keywords
buprenorphine
dosage form
dosage
pain relief
transdermales
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322102T
Other languages
German (de)
English (en)
Inventor
Bruce E Reidenberg
Daniel A Spyker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of DE60322102D1 publication Critical patent/DE60322102D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60322102T 2002-12-13 2003-12-15 Transdermales buprenorphin-dosierschema zwecks schmerzstillung Expired - Lifetime DE60322102D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43342302P 2002-12-13 2002-12-13
PCT/US2003/039792 WO2004054553A1 (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia

Publications (1)

Publication Number Publication Date
DE60322102D1 true DE60322102D1 (de) 2008-08-21

Family

ID=32595187

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322102T Expired - Lifetime DE60322102D1 (de) 2002-12-13 2003-12-15 Transdermales buprenorphin-dosierschema zwecks schmerzstillung

Country Status (16)

Country Link
US (1) US7270830B2 (enExample)
EP (1) EP1572167B1 (enExample)
JP (2) JP5054893B2 (enExample)
AT (1) ATE400258T1 (enExample)
AU (2) AU2003297073A1 (enExample)
CA (1) CA2510223C (enExample)
CY (1) CY1108384T1 (enExample)
DE (1) DE60322102D1 (enExample)
DK (1) DK1572167T3 (enExample)
ES (1) ES2310262T3 (enExample)
IL (1) IL169056A (enExample)
MX (1) MXPA05006334A (enExample)
NZ (1) NZ539936A (enExample)
PT (1) PT1572167E (enExample)
SI (1) SI1572167T1 (enExample)
WO (1) WO2004054553A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
JP5054893B2 (ja) * 2002-12-13 2012-10-24 ユーロ−セルティーク エス．エイ． 鎮痛のためのブプレノルフィン経皮投与計画
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
MXPA05011703A (es) * 2003-04-30 2006-01-23 Purdue Pharma Lp Forma de dosis transdermica resistente a los retardadores que comprende un componente de agente activo y un componente de agente adverso en el sitio distal de la capa del agente activo.
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
ATE375149T1 (de) * 2003-07-25 2007-10-15 Euro Celtique Sa Behandlung von entzug
EP1638492B1 (en) * 2003-07-25 2008-01-02 Euro-Celtique S.A. Preoperative treatment of post operative pain
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
WO2007070632A2 (en) * 2005-12-13 2007-06-21 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
SI2054031T1 (sl) 2006-07-21 2016-09-30 Biodelivery Sciences International, Inc. Transmukozne naprave za administracijo z izboljšanim vnosom
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
WO2009114118A2 (en) * 2008-03-08 2009-09-17 Theraquest Biosciences, Inc. Oral pharmaceutical compositions of buprenorphine and method of use
WO2010047681A1 (en) * 2008-10-24 2010-04-29 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
AU2012327247B2 (en) * 2011-12-12 2015-12-24 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
DE112014002664T5 (de) 2013-06-04 2016-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales Verabreichungssystem
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定
CN113811950A (zh) * 2018-12-14 2021-12-17 派尔疗法股份有限公司 优化含丁丙诺啡的产品的诱导的数字治疗组件

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
ATE131384T1 (de) * 1990-04-24 1995-12-15 Teijin Ltd Pflaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
JP2886021B2 (ja) * 1993-03-19 1999-04-26 帝三製薬株式会社 安定な貼付剤
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
JP2837337B2 (ja) * 1993-08-10 1998-12-16 帝三製薬株式会社 貼付剤
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
JP3662388B2 (ja) * 1997-05-30 2005-06-22 日東電工株式会社 経皮吸収製剤及びその製造方法
AU2003224742A1 (en) 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
JP5054893B2 (ja) * 2002-12-13 2012-10-24 ユーロ−セルティーク エス．エイ． 鎮痛のためのブプレノルフィン経皮投与計画
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
ATE375149T1 (de) * 2003-07-25 2007-10-15 Euro Celtique Sa Behandlung von entzug

Also Published As

Publication number Publication date
WO2004054553A1 (en) 2004-07-01
AU2003297073A1 (en) 2004-07-09
IL169056A (en) 2012-01-31
EP1572167A1 (en) 2005-09-14
ES2310262T3 (es) 2009-01-01
JP2010285457A (ja) 2010-12-24
WO2004054553A9 (en) 2005-09-15
DK1572167T3 (da) 2008-10-13
PT1572167E (pt) 2008-10-03
JP2006513184A (ja) 2006-04-20
EP1572167B1 (en) 2008-07-09
CY1108384T1 (el) 2014-02-12
SI1572167T1 (sl) 2008-12-31
CA2510223C (en) 2017-09-12
EP1572167A4 (en) 2007-01-10
AU2010201479A1 (en) 2010-05-06
MXPA05006334A (es) 2005-08-26
AU2010201479B2 (en) 2012-11-01
NZ539936A (en) 2007-06-29
US20040126416A1 (en) 2004-07-01
US7270830B2 (en) 2007-09-18
CA2510223A1 (en) 2004-07-01
ATE400258T1 (de) 2008-07-15
JP5054893B2 (ja) 2012-10-24

Similar Documents

Publication Publication Date Title
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
DK1642578T3 (da) Fentanyl salt-sammensætning til nasal administration
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
DK1032376T3 (da) Anvendelse af benzhydrylsulfinylderivater til behandling af søvnighed af medicinal oprindelse
EA200900272A1 (ru) Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
DK1263729T3 (da) Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme
DE60322436D1 (de) Verabreichung von capsaicinoiden
ATE398464T1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
NO20045240L (no) Transepikutan administrasjonsform for a behandle restless legs syndromet
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DK1646328T3 (da) Behandling af afhængighedsophör
SE9802208D0 (sv) Novel compounds
DE59911734D1 (de) Kombination von selen-haltigen verbindungen mit gemcitabin oder mitomycin c
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
SE9802209D0 (sv) Novel compounds
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
NO982863L (no) Nye forbindelser med analgetisk effekt
ATE293972T1 (de) Behandlung von chronischen schmerzen
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
SE0203817D0 (sv) New composition
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition